Sangamo Therapeutics (SGMO) to Release Quarterly Earnings on Thursday

Sangamo Therapeutics (NASDAQ:SGMO) will be announcing its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.09). The business had revenue of $2.04 million for the quarter, compared to the consensus estimate of $8.96 million. Sangamo Therapeutics had a negative net margin of 146.30% and a negative return on equity of 82.17%. On average, analysts expect Sangamo Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sangamo Therapeutics Trading Up 1.7 %

Shares of SGMO traded up $0.01 during trading hours on Tuesday, reaching $0.54. 294,928 shares of the company’s stock traded hands, compared to its average volume of 2,063,321. The firm’s 50 day simple moving average is $0.70 and its 200-day simple moving average is $0.59. The stock has a market cap of $111.10 million, a PE ratio of -0.36 and a beta of 1.40. Sangamo Therapeutics has a 12 month low of $0.29 and a 12 month high of $1.67.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SGMO. HC Wainwright restated a “buy” rating and issued a $5.00 target price (up previously from $3.00) on shares of Sangamo Therapeutics in a research report on Tuesday, March 19th. StockNews.com began coverage on Sangamo Therapeutics in a research report on Saturday, April 27th. They issued a “sell” rating for the company. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research report on Thursday, March 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Sangamo Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $5.67.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.